PPAR Agonists and Cardiovascular Disease in Diabetes
Figure 2
An increase in renal tubulointerstitial area associated with
streptozotocin diabetes in apoE KO mice is attenuated following treatment with
PPARγ agonist,
rosiglitazone, PPARα agonist,
gemfibrozil, or the dual PPARα/γ agonist, ragaglitazar.
